Addressing Critical Questions in Ovarian Cancer Research and Treatment

Continuing Medical Education (CME)

Accreditation Statement
The American Association for Cancer Research (AACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education activities for physicians.

Credit Designation Statement
The AACR has designated this live activity for a maximum of 20.0 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Credit certification for individual sessions may vary, dependent upon compliance with the ACCME Accreditation Criteria. The final number of credits may vary from the maximum number indicated above.

Claiming (CME) Credit
Physicians and other health care professionals seeking AMA PRA Category 1 Credit(s)TM for this live continuing medical education activity must complete the CME Request for Credit Survey by Wednesday, November 15, 2017. Certificates will only be issued to those who complete the survey. Your CME certificate will be sent to you via email after the completion of the activity.

Statement of Educational Need, Target Audience, and Learning Objectives
Although ovarian cancer is relatively rare compared to other cancer types, accounting for an estimated 1.3% of all new cancer cases in 2017, ovarian cancer is the fifth leading cause of cancer-related deaths among women. Due to challenges in early detection, more than 60% of ovarian cancer cases are diagnosed at an advanced stage, resulting in a lower survival rate. The overall 5-year survival rate is 46%, however, in the instance of early diagnosis of localized disease, the 5-year survival rate increases to 92%. These data call on the need for an improvement of early-detection testing and identification of high-risk individuals to diagnose patients at the earliest stage possible and increase the likelihood of treatment success.

The treatment of ovarian cancer has expanded beyond first-line surgery, chemotherapy , and radiation due, in large part, to continued collaboration and advancements from basic and translational scientists in areas such as DNA damage/repair, identification of molecular drivers, and immunology.

Despite progress in the treatment of ovarian cancer in the last two years, critical unanswered questions remain. For example, some ovarian cancers, specifically high-grade serous ovarian cancers, are particularly susceptible to PARP inhibitors, and as many as 50% of HGSCs have underlying defects in DNA repair. Identification of predictors of PARP inhibitor response and resistance, elucidation of PARP inhibitor resistance mechanisms, and the rationale for combination-therapy strategies to enhance the effectiveness of PARP inhibitors are all important unanswered questions.

In addition, new knowledge has emerged in DNA damage and repair, metabolic changes in ovarian cancer cells and stroma, tumor microenvironment, autophagy, and the genotype and phenotype of rare ovarian cancers.

With these advances, it is critical to assess these basic research underpinnings that inform clinical therapeutics, as well as, discuss how observations from clinical practice can be back-translated into subsequent basic mechanistic research.

This conference is becoming a "must-attend" event that attracts basic, translational and clinical ovarian cancer investigators from around the world. Attending this program provides the opportunity to hear the latest research from leading national and international experts, and also help build collaborations to advance the prevention, detection and treatment of this deadly disease. Attendees will be exposed to an extremely stimulating and interactive environment, enabling the exchange of ideas and fostering partnerships to bridge the gap between discovery and therapy.

After participating in this CME activity, physicians should be able to:


1. Analyze current basic and translational cancer research in the fields of DNA damage and repair, genetics and molecular drivers, metabolic changes in and the tumor microenvironment of ovarian cancer  and identify potential applications to the clinic.

2. Provide examples of the latest research in immunotherapy for ovarian cancer.

3. Articulate current approaches to assess the resistance and response to therapy.

4. Demonstrate knowledge of current advances the prevention and early detection of ovarian cancer.

5. Identify vulnerabilities in rare ovarian tumor types that can be exploited therapeutically.

Disclosure Statement
It is the policy of the AACR that the information presented at AACR CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, the AACR will provide information that Program Committee members and speakers have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity. This disclosure information will be made available in the Program/Proceedings of this conference.

Acknowledgement of Financial or Other Support
This activity is supported by grants and will be disclosed at the activity.

Questions about CME?
Please contact the Office of CME at 215-440-9300 or​​​